NASDAQ •
Healthcare •
Biotechnology •
Quote as of 06/30/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization270.91 mln
Float9.49 mln
Earnings Date08/12/2026
Piotroski F-Score
1
/ 9
Very weak
Beneish M-Score
-3.71
Highly reliable
Relative Strength
77
/ 100
Strongly outperforming
Debt / Equity
0.14
Very low leverage
ROE
-82.89
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Lyell Immunopharma is a clinical-stage biotechnology company focused on developing advanced cell-based treatments for patients with blood cancers and solid tumors. Its most advanced therapy, rondecabtagene autoleucel, targets two proteins found on cancer cells and is currently being tested across multiple clinical trials for large B-cell lymphoma. The company is also developing LYL273, a CAR T-cell treatment aimed at colorectal cancer that has progressed despite prior therapies. Founded in 2018 and based in South San Francisco, Lyell applies several proprietary techniques designed to make T cells more durable and effective against tumors.
